Clinical Trial Detail

NCT ID NCT03816358
Title Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

pancreatic adenocarcinoma

Therapies

Anetumab ravtansine + Gemcitabine + Nivolumab

Anetumab ravtansine + Nivolumab

Anetumab ravtansine + Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.